Independence or the other carcinostatic substance and/or jointly using hypoxia activated die professional drag of TH 302 and the like with radiotherapy, the cancer can be dealt with by prescribing. With combined use medical therapy, it is possible to prescribe another carcinostatic substance from hypoxia activated die professional drag or radiotherapy during period of the same 24 hours, to the other carcinostatic substance or before the starting the dosage of the radiotherapy to end the dosage of hypoxia activated die professional drag is possible. In one feature, this invention, another chemical compound of TH 302 or formula I (10mg/mL - approximately 300mg/mL), ethanol (70% - 95%), the non ion surface active agent (TWEEN 80 and the like is included) (5% - 10%), and the other medicine of 1 types or more (dimethyl acetamide and the like) the stability which offers the liquefied constituent with option.TH-302などの低酸素活性化型プロドラッグを単独あるいは他の抗がん剤および/または放射線療法と併用して投与することによってがんが処置され得る。併用療法では、低酸素活性化型プロドラッグと別の抗がん剤または放射線療法を同じ24時間の期間内に投与してもよく、他の抗がん剤または放射線療法の投与の開始前に低酸素活性化型プロドラッグの投与を終了してもよい。一態様において、本発明は、TH-302または式Iの別の化合物(10mg/mL~約300mg/mL)、エタノール(70%~95%)、非イオン界面活性剤(TWEEN 80など)(5%~10%)、および任意選択で1種類以上の他の薬剤(ジメチルアセトアミドなど)を含む安定な液状組成物を提供する。
